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Background: Although surgical endarterectomy remains the treatment of choice for carotid
artery stenosis, carotid artery stenting (CAS) with use of proximal protection systems (PPS)
plays an very important role as alternative treatment modality, especially in patients with
critical, symptomatic lesions.
This study was single-centre study to evaluate the technical and clinical success of
proximal protection devices as the ﬁrst choice for embolic protection in symptomatic and
asymptomatic carotid stenosis in patients with bilateral, advanced lesions of carotid arteries
(bilateral stenoses or stenosis and occlusion).
Methods: This was a post hoc analysis, with 30-day follow up. We analyzed results of
treatment of 38 patients who underwent 38 CAS with PPS, 17 such procedures in asymp-
tomatic (group A), and 21 in symptomatic individuals (group B). The GORE® Flow Reversal
System (W.L. Gore, Flagstaff, AZ, USA) was used in 2 patients, and the Mo.Ma Ultra device
(Medtronic, Minneapolis, MN, USA) in 36 patients. Mean age was 68  7 years, 65% percent of
patient were male.
Results: There were no procedural and during 30-day follow-up neurologic events. Intoler-
ance of occlusion system occurred in 4 patients (11%) in both groups with any later
symptoms. Risk factors of this adverse event comprised: lesions of the left internal carotid
lesion and coexisiting diabetes mellitus.
Conclusions: CAS in high risk patients with bilateral lesions of carotid arteries with the use of
PPS seems to be a relatively very safe procedure.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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Carotid angioplasty and stenting is an alternative treatment
modality for the management of stenosis of the carotid artery
and plays an important role in stroke prevention. Stenting of
carotid artery is particularly preferred in patients presenting
with high risk of surgical endarterectomy. Carotid angioplasty
and stenting is also used for the treatment of other, non-
atherosclerotic lesions of these arteries [1–4]. A number of
trials demonstrated that the use of proximal protection
systems (PPS) during carotid stenting is safe and effectively
protects the brain from ischemic events during the procedure
[5–8]. Still, this type of protection is difﬁcult to use in a case of
contralateral stenosis or occlusion, and therefore in many
such patients an alternative protection system is utilized. In
this retrospective study we analyzed the results of treatment
in selected patients presenting with signiﬁcant bilateral steno-
ses, or stenosis and contralateral occlusion of the internal carotid
arteries (ICA), with the procedure performed using PPS.
2. Aim
This post hoc analysis, with 30-day follow-up, was aimed at
assessment of safety and efﬁcacy of stent implantation for the
treatment of atherosclerotic stenoses of the ICAs coexisting
with signiﬁcant contralateral lesions, with the use of a PPS, and
also at identiﬁcation of risk factors associated with such an
endovascular technique in these high-risk patients.
3. Patients and methods
We reviewed our register of endovascular interventions and
identiﬁed 38 patients with bilateral signiﬁcant lesions of the
ICAs who were managed with the use of PPS. From March
2011 to December 2016 there were 38 such patients, 25 males
and 13 females, aged 68  7 years, 2 of them (5%) were older
than 80 years.Fig. 1 – A patient with bilateral, asymptomatic carotid lesions. (A
subtotal stenosis of the left internal carotid artery; (C) Mo.Ma sy
implantation of Carotid Wallstent on the left side.The primary endpoint of this analysis was the proportion of
patients who had stroke or stroke-related death. We included
all types of strokes, both ipsi- and contralateral, as well as
minor, major and fatal strokes. The secondary endpoint was
the proportion of patients who had myocardial infarction (both
STEMI and non-STEMI events) or a death that was not caused
by stroke. In addition to demographic and clinical data of the
patients, we analyzed angiographic characteristics, such as
presence of coexisting lesions in other arteries supplying the
brain, including intracranial stenoses. Also, we assessed
endovascular technique used (type of protection, type of
stent, duration of the procedure, duration of occlusion of the
artery, etc.).
Out of 38 endovascular stent implantations with the use of
PPS in this particular patient group, 17 such procedures were
performed in asymptomatic patients and 21 in symptomatic
ones. Twelve symptomatic patients had a stroke and nine
patients presented with a history of transient ischemic
attack. The time from an ischemic event to endovascular
procedure was 5–190 days, mean time: 45 days. Degree of
stenosis of the ICA revealed by initial angiography ranged
from 65 to 100% (mean: 93.9  8.3%), thus subtotal stenoses
prevailed in these patients. One asymptomatic and three
symptomatic patients had contralateral ICAs totally occlud-
ed. Other patients presented with severe stenoses of these
arteries – on average 75.5  14% stenosis in asymptomatic
patients and 78.3  13% (Fig. 1) in symptomatic ones (Fig. 2).
Clinical characteristics of patients and potential risk factors
are presented in Table 1 and comparison between asymp-
tomatic and symptomatic patients regarding these risk
factors is given in Table 2.
Standard preprocedural management of patients com-
prised multidisciplinary assessment, including neurological,
vascular and cardiologic consultations. Potential risks and
beneﬁts associated with the planned procedure were dis-
cussed with patients, and all of them gave their written
informed consent. Neurological assessment was performed at
least before the procedure and on the ﬁrst postprocedural day.
Sonographic follow-up of the treated arteries was performed
on the day of procedure, and then after 1 and 6 months.) Critical stenosis of the right internal carotid artery; (B)
stem introduced on the left side; and (D) final result after
Table 1 – Clinical characteristics of the patients and
potential risk factors; number of patients: N = 38.
Comorbidities and potential risk factors N %
Stable coronary heart disease 10 26.3
Arterial hypertension 32 84.2
Diabetes mellitus type 2 11 28.9
Dislipidemia 26 68.4
Cigarette smoking 10 26.3
Renal impairment 2 5.2
Peripheral artery disease 3 7.9
History of percutaneous coronary angioplasty 3 7.9
History of coronary artery bypass graft surgery 1 2.6
History of myocardial infarction 4 10.5
Symptomatic carotid artery stenosis 19 0.5
History of transient ischemic attack 9 23.7
History of stroke 10 26.3
Bilateral stenosis of the internal carotid artery 31 81.6
Occlusion of the internal carotid artery 3 7.9
Stenosis of the vertebral artery 2 5.2
Fig. 2 – Patient with symptomatic stenosis of the left side and a critical lesion of the right internal carotid artery. (A) Critical
narrowing of the right internal carotid artery; (B) critical symptomatic stenosis of the left internal carotid artery; (C) Mo.Ma
system – occlusion of left external artery; and (D) final result after implantation Precise RX stent.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 3 7 5 – 3 8 1 377Two types of PPS were utilized: the Mo.Ma (Medtronic,
Minneapolis, MN, USA) and the Gore Flow Reversal System
(Gore & Associates, Inc., Flagstaff, AZ, USA). The ﬁrst system
protects the brain against embolization thanks to stopped ﬂow
in the ICA, which occurs after the balloons of this system are
expanded in the common and external carotid arteries. In the
case of the Gore Flow system, there is a ﬂow reversal in the ICA,
which results from temporary shunting from the ICA to the
femoral vein through catheters and ﬁlter of this device.
Proximal protection was chosen in patients presenting with
subtotal stenoses of the ICA, tortuous carotid arteries,
thrombotic and other unstable lesions, and also in othercases where the use of distal protection was not technically
feasible. In one particular patient we utilized both proximal
and distal (SpiderFX; Covidien, ev3 Endovascular, Inc., Ply-
mouth, MN, USA) protections. An average time of closure of the
common carotid artery by protection system was 7.5  3.8 min
(2.1–11.2 min), still a longer time of occlusion regarded earlier
interventions and with better expertise and modiﬁed tech-
nique this time in latter patients was shortened to 5.2
 2.5 min. In 17 patients (45%) PPS captured macroscopically
detectable embolic material (Table 3). In all patients we
implanted self-expandable stents, primarily with a close-cell
design. A predilatation before stent implantation was needed
in 11 patients (29%) and postdilatation in all patients. After the
procedure residual stenosis in all patients was less that 20%.
4. Statistical analysis
Statistical analysis was performed using the SPSS software
(Statistical Package for the Social Sciences (version 23.0, SPSS
Inc., Chicago, IL, USA)). Continuous variables were expressed
as means  standard deviation; categorical variables were
expressed as percentages. Analysis of normality was performed
with the Kolmogorov–Smirnov test. Comparison of categorical
variables between the groups was performed using the chi-
square test. Comparisons of continuous variables between the
two groups were performed using the independent sample t-
test. Multivariate, stepwise backward conditional logistic
regression analysis was used to determine independent pre-
dictors of successful intervention. All signiﬁcant parameters in
the univariate analysis were selected in the multivariate model.
The signiﬁcance of the two-tailed p was set at p < 0.05.
Table 2 – Risks factors in asymptomatic vs. symptomatic patients (NS – the difference was not statistically significant).
Risk factor Asymptomatic patients
(17 procedures)
Symptomatic patients
(21 procedures)
p value
Patients' age (in years) 68.7  6.7 67.5  8.0 NS
Patients aged >80 years 1 1 NS
Patients aged <60 years 2 7 NS
Male gender 9 13 NS
Stable coronary heart disease 4 6 NS
Congestive heart failure 2 1 NS
Cigarette smoking 5 7 NS
Diabetes mellitus type 2 5 6 NS
Arterial hypertension 13 18 NS
Dislipidemia 10 16 NS
Renal impairment 1 1 NS
Peripheral arterial disease 2 1 NS
History of myocardial infarction 2 2 NS
History of percutaneous coronary angioplasty 1 2 NS
History of coronary artery bypass graft surgery 0 1 NS
Contralateral stenosis of the internal carotid artery 16 18 NS
Occlusion of the internal carotid artery 1 3 NS
Stenosis of the vertebral artery 2 0 NS
Table 3 – Characteristics of stents utilized and embolic material captured by protection system in asymptomatic vs.
symptomatic patients (NS – difference statistically not significant).
Asymptomatic patients (17) Symptomatic patients (21) p value
Stents (brand)
Precise (Cordis, Fremont, CA, USA) 5 5 NS
Carotid Wallstent (Boston Scientiﬁc, Natick, MA, USA) 7 11 NS
Cristallo Ideale (Medtronic, Minneapolis, MN, USA) 5 5 NS
Stents (design)
Close-cell design stents 12 16 NS
Open-cell stents 5 5 NS
Macroscopically visible embolic material in protection system
Single plaque or thrombus 6 10 NS
A little of debris 0 1 NS
Table 4 – Complications during endovascular procedure and during 30 days follow-up in asymptomatic vs. symptomatic
patients; (difference between the groups was not statistically significant).
Adverse events Asymptomatic
patients (17)
Symptomatic
patients (21)
Mild reversible neurological symptoms after introduction of the protection system 2 2
Periprocedural hypotension 1 2
Any fatality 0 0
Stroke 0 0
Transient ischemic attack 0 0
Myocardial infarction 0 0
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Four patients (11%) developed neurological symptoms after
introduction of the PPS, but these symptoms of intolerance
were present only during occlusion of the protection system
and did not result in further clinical consequences. Also, 3
patients (7.8%) developed periprocedural hypotension, which
in one case required an intravenous administration of
dopamine. Apart from these rather minor events, there were
no serious periprocedural complications.There were no fatalities during 30-day follow-up. Patients
were advised to report any neurological events that occurred
during this period. They neither developed a stroke, nor did
they suffer from milder neurologic ischemic events or other
serious non-neurologic complications during 30-day follow-
up. Details are given in Table 4.
Logistic multivariate analysis revealed some risk factors
signiﬁcantly predisposing for above-presented periproce-
dural complications. These comprised left-sided lesions
(HR = 8.12; p = 0.02) and coexisting diabetes mellitus
(HR = 7.36; p = 0.03).
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Retrospective and open-label design of this study appears to be
its main limitation. Also, the group of patients assessed was
not homogenous and rather mirrored everyday clinical
practice. By the same token, endovascular armamentarium
and periprocedural pharmacological management were not
standardized but patient-tailored. Nevertheless, our results
indicate that carotid artery stenting in patients presenting
with bilateral severe lesions can be performed safely and
efﬁciently using the PPS. Similarly to other authors we opt for
obligatory use of protection systems during carotid artery
stenting [5,6,9]. In our patient series we found macroscopic
embolic material captured by PPS quite frequently, in 6
asymptomatic (35.3.0%) and 11 symptomatic (52.4%) patients
(Table 3), thus a potential risk of periprocedural embolic stroke
in these patients was very high. Although for the time being
distal protection devices are predominantly used, there is a
growing body of evidence supporting the use of PPS during
carotid angioplasty and stenting. This concept is supported by
a low rate of neurologic adverse events during such procedures
with the use of proximal protection. Bijuklic et al. [10]
compared distal and proximal protection systems and found
that the latter mode was associated with signiﬁcantly fewer
postprocedural cerebral lesions (45.2% vs. 87.1%; p = 0.001)
revealed by means of diffusion MR imaging. Similarly,
Montorsi et al. [11] who compared PPS (the Mo.Ma) with distal
protection system (the FilterWire), demonstrated that there
were signiﬁcantly fewer (13% vs. 93%) periprocedural embolic
events if proximal protection were applied.
Since there were no serious complications amongst our
patients, we can only discuss risk factors associated with
minor adverse events. These risk factors comprised left-sided
lesions and diabetes mellitus. Other researchers found that
adverse events after carotid stenting with the use of PPS were
more likely in patients with bilateral lesions, aged more than
80 years, presenting with long lesions and a history of
myocardial infarction [5,6,8].
Metaanalysis by Bersin et al., which was published in 2012
and discussed results of carotid stenting with the use of PPS in
2397 patients, reported stroke rate during 30-day follow-up at
the level of 1.71% and incidence of stroke, death or myocardial
infarction at the level of 2.6%. In this metaanalysis diabetes
mellitus and advanced patient's age were found to be
associated with an increased risk of adverse events [12]. A
similar metaanalysis by Hornung et al. [13], who studied
efﬁcacy of PPS in 124 patients, reported one stroke (0.8%)
during 30-day follow-up (of note, in this particular case an
open-cell stent was implanted). In the study published by
Stabile et al. the Mo.Ma system was used in 1300 patients. The
composite complication rate (comprising stroke and death) at
30-day follow-up was 1.4% (3% in symptomatic patients and
0.9% in asymptomatic ones) and was not increased in elderly
individuals. By contrast, a low operator experience (less than
100 procedures performed) and symptomatic lesions were
associated with a higher risk of adverse events [14]. In the
randomized multicenter study ARMOUR, which evaluated a
group of 222 patients (15% of them were symptomatic, 29%
were older than 80 years; occlusion or stenosis of thecontralateral artery constituted an exclusion criterion for
the use of PPS) the composite complication rate (comprising
stroke, death and myocardial infarction) was 2.7%, and stroke
rate at 30 days follow-up was 0.9% [7]. Efﬁcacy and safety of the
Gore Flow Reversal System have been evaluated in the
multicentre prospective, nonrandomized study EMPiRE [15].
In this study 245 patients have been studied, including 30%
symptomatic and 16% older than 80 years. In this study
contralateral stenosis or occlusion of the ICA was not an
exclusion criterion; quite the contrary, actually 10.5% of
patients enrolled presented with an occlusion of the contra-
lateral ICA. Composite complication rate in this study
(including stroke, death, myocardial infarction or TIA) during
30-day follow-up was 4.5%. Composite complication rate
comprising only stroke and death was 2.9% (still, not a single
patient in this study developed a major stroke). The death/
stroke rates in this study in the symptomatic, asymptomatic
and patients older than 80 years were 2.6%, 3% and 2.6%,
respectively [15].
In our potentially high-risk patients presenting with
bilateral stenoses of the ICAs, results at 30 days follow-up
were at least as good as in the above-presented large group
studies. There were neither strokes nor fatalities, also
intolerance of PPS was relatively infrequent (in the AROMOUR
study intolerance of proximal protection was seen in 13.8% of
patients, despite the fact that individuals presenting with
bilateral lesions were not managed using this type of
protection [7]). In the EMPiRE study [15] a contralateral stenosis
of the ICA did not constitute an exclusion criterion for the use
of PPS, still in this study incidence of serious adverse events,
such as stroke or death, was quite high.
An increased risk of adverse events in diabetics, which was
also revealed in the metaanalysis published by Bersin et al.,
probably reﬂects more aggressive course of arterial disease in
the settings of diabetes mellitus [11]. An unsuspected ﬁnding
of our survey was the fact that all four cases of intolerance of
PPS, manifesting with neurological symptoms occurring after
introduction of the device into the carotid artery, were seen in
patients managed for the lesions of the left ICA. It remains
unclear if the left ICA is indeed more prone to such adverse
events. It is also possible that it is easier to diagnose a mild left-
sided cerebral ischemia, since non-paretic clinical symptoms
of the left cerebral hemisphere ischemia, such as dysphasia,
are more obvious than the symptoms of ischemia of right
hemisphere (comprising linguistic deﬁcit, decreased attention,
anosognosia, prosopagnosia or other complex deﬁcits, which
require a thorough and time-consuming neurological assess-
ment to be revealed). Nonetheless, there were only a few such
intolerances of PPS amongst our patients. We believe that a
relatively low incidence of these adverse events could be
explained by some modiﬁcations of endovascular technique
used. In each patient we tried to postpone the closure of the
common carotid artery until the guidewire and stent were
introduced into the distal part of the system. This enabled a
shorter average time of the occlusion – 5.2 min instead of
7.5 min. A selective use of both proximal and distal protection
system is also an option aimed at minimizing the rate of
complications. Such a dual protection has already been shown
to be safe and effective [16,17]. Importantly, a high experience
of operators could potentially play a role. Stabile et al. [14] have
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 3 7 5 – 3 8 1380reported that adverse events after carotid stenting with the
use of PPS are less likely when the procedure is performed by
operators who have already performed more than 100 such
treatments. Expertise of the operator as an independent factor
associated with reduced complication rate has also been
demonstrated by other studies, and there seems to be a
learning curve with signiﬁcant drop in the incidence of adverse
events with more than 200 procedures performed [5–7,18–20].
We utilized lesion-tailored stents, preferentially closed-cell
ones. Although we did not observe different clinical outcomes
in patients managed with closed- vs. open-cell stents, other
researchers revealed better results after implantation of
closed-cell devices [21]. Recently, a new generation of carotid
stents has been marketed; they combine small area of the cells
with ﬂexibility characteristic for open-cell devices, which
potentially could improve results of carotid stenting [21,22].
7. Conclusions
Results of this retrospective analysis suggest that proximal
protection is a safe treatment modality for carotid artery
stenting in patients with bilateral stenoses of the ICA. Still,
only a prospective study comparing the results of different
types of protection systems could guide the treatment in this
unique group of patients.
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